$369.43 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter

Share on StockTwits

Wall Street analysts forecast that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will report $369.43 million in sales for the current quarter, according to Zacks. Ten analysts have issued estimates for BioMarin Pharmaceutical’s earnings, with the lowest sales estimate coming in at $351.51 million and the highest estimate coming in at $382.70 million. BioMarin Pharmaceutical reported sales of $334.15 million in the same quarter last year, which indicates a positive year-over-year growth rate of 10.6%. The business is scheduled to report its next quarterly earnings report after the market closes on Thursday, October 25th.

On average, analysts expect that BioMarin Pharmaceutical will report full-year sales of $1.51 billion for the current year, with estimates ranging from $1.49 billion to $1.53 billion. For the next year, analysts expect that the firm will report sales of $1.72 billion, with estimates ranging from $1.65 billion to $1.78 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). BioMarin Pharmaceutical had a negative net margin of 8.68% and a negative return on equity of 3.00%. The business had revenue of $372.80 million during the quarter, compared to analyst estimates of $359.25 million. During the same quarter last year, the company posted ($0.21) earnings per share. The company’s revenue was up 17.4% on a year-over-year basis.

A number of brokerages have issued reports on BMRN. Jefferies Financial Group increased their price objective on shares of BioMarin Pharmaceutical to $125.00 and gave the stock a “buy” rating in a research note on Tuesday. They noted that the move was a valuation call. Cantor Fitzgerald set a $126.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Monday. BidaskClub upgraded shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Zacks Investment Research downgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. Finally, ValuEngine upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday, October 3rd. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $116.61.

BMRN stock opened at $103.82 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.24 and a current ratio of 2.83. BioMarin Pharmaceutical has a 52 week low of $75.81 and a 52 week high of $106.74. The stock has a market capitalization of $17.22 billion, a P/E ratio of -157.91 and a beta of 1.61.

In other news, EVP Robert Baffi sold 5,173 shares of the stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $105.00, for a total value of $543,165.00. Following the completion of the transaction, the executive vice president now owns 83,276 shares of the company’s stock, valued at $8,743,980. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey Robert Ajer sold 1,000 shares of the stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $98.98, for a total transaction of $98,980.00. Following the completion of the transaction, the executive vice president now directly owns 49,135 shares of the company’s stock, valued at approximately $4,863,382.30. The disclosure for this sale can be found here. Insiders sold 75,023 shares of company stock valued at $7,497,878 in the last three months. Company insiders own 1.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of BMRN. Huntington National Bank bought a new position in shares of BioMarin Pharmaceutical in the third quarter worth about $105,000. BDO Wealth Advisors LLC bought a new position in shares of BioMarin Pharmaceutical in the second quarter worth about $127,000. Financial Gravity Wealth Inc. bought a new position in shares of BioMarin Pharmaceutical in the first quarter worth about $195,000. Allen Investment Management LLC bought a new position in shares of BioMarin Pharmaceutical in the second quarter worth about $203,000. Finally, Reilly Financial Advisors LLC bought a new position in shares of BioMarin Pharmaceutical in the second quarter worth about $254,000.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Featured Article: Fiduciary

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply